Immunomedics Says IMMU-130 Produced Partial Response in One Patient, Response Duration 4.7 Months
AMSTERDAM, Netherlands, Sept. 30, 2013 (GLOBE NEWSWIRE) -- Immunomedics, Inc. (Nasdaq: IMMU), a biopharmaceutical company primarily focused on the development of monoclonal antibody-based products for the targeted treatment of cancer, autoimmune and other serious diseases, today presented encouraging results from a Phase I dose-escalation trial of its proprietary antibody-drug conjugate (ADC), labetuzumab-SN-38, or IMMU-130, in patients with metastatic colorectal cancer. Dr. Neil H. Segal at the Memorial Sloan-Kettering Cancer Center, New York, NY, reported the updated results at The European Cancer Congress 2013 in Amsterdam, The Netherlands.
Results from 15 very advanced patients who were progressing after prior therapies, including irinotecan, were presented at the Congress. Only 5 patients to-date have been evaluated after completing therapy with 4 or more doses of the ADC, administered once every 2 weeks, with the rest having advancing disease that precluded further therapy. Even at this early stage of clinical development, IMMU-130 has produced a partial response in 1 patient with a duration of response of 4.7 months, or 140 days. This patient had failed multiple prior therapies, including irinotecan.
"We are encouraged by these early results, which appear to show that IMMU-130 is well tolerated within a clinically effective dosage range, and may be active